Yajing Chen has sold ZLAB and made no open-market buys since Jun 2024

Yajing Chen, Ph.D., is the Chief Financial Officer of Zai Lab Ltd (NASDAQ: ZLAB; HKEX: 9688), a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines.( She was promoted to CFO effective July 7, 2023, after serving as Senior Vice President and Deputy Chief Financial Officer since joining Zai Lab in September 2021, where she oversaw finance, planning and forecasting, accounting, tax, treasury, and procurement.( As CFO, she leads Zai Lab’s global finance organization and is responsible for finance, accounting, treasury, internal audit, and procurement, including capital allocation and strategic planning to support the company’s growth and path to profitability.( She is also a reporting corporate insider whose equity compensation includes American Depositary Shares (ADSs) and Restricted Share Units, with recent Form 4 filings reflecting routine RSU vesting and related tax-cover sales.(

Chen is a seasoned finance executive with more than 20 years of experience in the life sciences industry, combining deep sector expertise with a scientific research background.( Before joining Zai Lab, she spent 2006–2021 at AstraZeneca, holding progressively senior roles, including Chief Financial Officer for the U.S. Oncology Business Unit (2019–2021) and Finance Controller of the Global Oncology Business Unit (2016–2019).( Earlier in her career she worked at Quest Diagnostics, further building her healthcare finance experience.( Chen holds a Ph.D. in Microbiology from New York University, an MBA from Columbia Business School, and a B.S. in Biology from Wuhan University, and is fluent in English and Chinese.( Her background as a Ph.D.-trained scientist and global finance leader positions her as a key strategic partner to Zai Lab’s executive team in the biopharmaceutical sector.(

Written by Perplexity from public sources.